SL POGEN, Inc.

SL POGEN, Inc. (SLPG) is a Contracted Development & Manufacturing Organization (CDMO) specialized in nucleotide drug development. JV among Genexine–Korea’s leading biotech, POSTECH–world-class science tech university, and Kalbe–ASEAN’s biggest pharma, established in 2020, located in South Korea. As getting commercialization of nucleotide medicines, the highest level of Chemical Manufacturing Control (CMC) infrastructure and potentials are required to nucleotide drug development, also requires commercial scale of manufacture. SLPG inherited its proprietary technology and know-how from Genexine, possesses a cutting-edge technology platform in DNA vaccines, and its CMC capability to conduct world-class clinical studies / Multi-Regional Clinical Trials (MRCT). SLPG is currently focusing on i) CDMO business in DNA medicines, ii) Nucleotide (NT) sourcing in nucleotide medicines.